|6.45||+0.4100||+6.79%||Vol 99.19K||1Y Perf 104.78%|
|Dec 2nd, 2022 16:00 DELAYED|
|- -||-0.32 -4.96%|
|Target Price||6.00||Analyst Rating||Moderate Buy 2.50|
|Potential %||-6.98||Finscreener Ranking||★+ 43.36|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★+ 42.87|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★+ 42.65|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||48.51||Earnings Rating||Neutral|
|Market Cap||249.02M||Earnings Date||8th Nov 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.19|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||71.09K|
|Avg. Monthly Volume||105.05K|
|Avg. Quarterly Volume||133.22K|
Voyager Therapeutics Inc. (NASDAQ: VYGR) stock closed at 6.45 per share at the end of the most recent trading day (a 6.79% change compared to the prior day closing price) with a volume of 99.19K shares and market capitalization of 249.02M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 186 people. Voyager Therapeutics Inc. CEO is G. Andre Turenne.
The one-year performance of Voyager Therapeutics Inc. stock is 104.78%, while year-to-date (YTD) performance is 138.01%. VYGR stock has a five-year performance of -55.33%. Its 52-week range is between 2.54 and 10.6, which gives VYGR stock a 52-week price range ratio of 48.51%
Voyager Therapeutics Inc. currently has a PE ratio of -12.10, a price-to-book (PB) ratio of 2.69, a price-to-sale (PS) ratio of 3.05, a price to cashflow ratio of 19.50, a PEG ratio of 2.32, a ROA of -9.30%, a ROC of -14.45% and a ROE of -20.42%. The company’s profit margin is -24.21%, its EBITDA margin is -19.50%, and its revenue ttm is $70.53 Million , which makes it $1.83 revenue per share.
Of the last four earnings reports from Voyager Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.19 for the next earnings report. Voyager Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Voyager Therapeutics Inc. is Moderate Buy (2.5), with a target price of $6, which is -6.98% compared to the current price. The earnings rating for Voyager Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Voyager Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Voyager Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 24.57, ATR14 : 0.39, CCI20 : 209.52, Chaikin Money Flow : -0.04, MACD : 0.13, Money Flow Index : 79.34, ROC : 16.64, RSI : 67.96, STOCH (14,3) : 100.00, STOCH RSI : 1.00, UO : 60.34, Williams %R : 0.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Voyager Therapeutics Inc. in the last 12-months were: Glenn F. Pierce (Sold 9 512 shares of value $63 730 ), Julie Burek (Sold 7 127 shares of value $35 465 ), Michael J. Higgins (Sold 13 891 shares of value $93 070 ), Robert W. Hesslein (Sold 15 093 shares of value $89 566 ), Robin Swartz (Sold 5 940 shares of value $49 201 )
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.